The total return over the past 12 months is +25.53% vs. +17.49% for the S&P 500. So far it's up +4.02% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +25.53% | +31.02% | +19.17% | +15.50% | +17.83% | +15.80% |
| Total Return CAGR | +25.53% | +31.02% | +19.17% | +15.50% | +17.83% | +15.80% |
| Revenue CAGR | +2.49% | +14.32% | +14.68% | +7.21% | +10.70% | +17.02% |
| Net Income CAGR | +5.54% | +14.57% | +22.73% | +2.64% | +16.10% | +17.17% |
| EPS CAGR | +9.09% | +23.53% | +20.93% | +7.83% | +20.27% | +16.46% |
| Free Cash Flow CAGR | +2.05% | +17.51% | +14.31% | +9.96% | +10.90% | +16.77% |
| Operating Cash Flow CAGR | +22.89% | +24.75% | +22.34% | +13.28% | +13.27% | +18.08% |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
United Therapeutics Corporation (UTHR)
| Year | Start price | End price | UTHR Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $487.25 | $506.82 | +4.02% | +11.72% | (7.70%) |
| 2025 | $352.84 | $487.25 | +38.09% | +17.72% | +20.37% |
| 2024 | $219.89 | $352.84 | +60.46% | +24.89% | +35.57% |
| 2023 | $278.09 | $219.89 | (20.93%) | +26.19% | (47.12%) |
| 2022 | $216.08 | $278.09 | +28.70% | (18.17%) | +46.87% |
| 2021 | $151.79 | $216.08 | +42.35% | +28.74% | +13.61% |
| 2020 | $88.08 | $151.79 | +72.33% | +18.37% | +53.96% |
| 2019 | $108.90 | $88.08 | (19.12%) | +31.22% | (50.34%) |
| 2018 | $147.95 | $108.90 | (26.39%) | (4.56%) | (21.83%) |
| 2017 | $143.43 | $147.95 | +3.15% | +21.70% | (18.55%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
